A case of recurrent gastric cancer successfully treated with TS-1

T. Onoda, S. Okamura, N. Takakura, S. Shiozaki, S. Ohno, K. Higaki, M. Ninomiya, Tetsuo Ikeda, N. Kobayashi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A patient with recurrent gastric cancer which infiltrated the pelvic muscle after the treatment of paraaortic lymph node and ovarian metastases was successfully managed by a novel oral anticancer drug, TS-1. TS-1 was administered at a dose of 80 mg/day. One course consisted of two repetitions of consecutive administration of TS-1 for 14 days and withdrawal of TS-1 for 14 days. Adverse reactions were mild and the patient did not request hospitalization after two courses had been completed. Subjective symptoms such as difficulty in walking improved after one week and a partial response was obtained after 2 weeks of treatment. At the end of 4 courses we could remove an indwelling pyelocatheter for the ureter stricture. As of 14 months after the beginning of administration of TS-1, the patient is being treated as an outpatient and has attained a better QOL than before.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume28
Issue number4
Publication statusPublished - Jan 1 2001

Fingerprint

Stomach Neoplasms
Mobility Limitation
Ureter
Pathologic Constriction
Hospitalization
Outpatients
Lymph Nodes
titanium silicide
Neoplasm Metastasis
Muscles
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Onoda, T., Okamura, S., Takakura, N., Shiozaki, S., Ohno, S., Higaki, K., ... Kobayashi, N. (2001). A case of recurrent gastric cancer successfully treated with TS-1. Gan to kagaku ryoho. Cancer & chemotherapy, 28(4), 539-542.

A case of recurrent gastric cancer successfully treated with TS-1. / Onoda, T.; Okamura, S.; Takakura, N.; Shiozaki, S.; Ohno, S.; Higaki, K.; Ninomiya, M.; Ikeda, Tetsuo; Kobayashi, N.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 28, No. 4, 01.01.2001, p. 539-542.

Research output: Contribution to journalArticle

Onoda, T, Okamura, S, Takakura, N, Shiozaki, S, Ohno, S, Higaki, K, Ninomiya, M, Ikeda, T & Kobayashi, N 2001, 'A case of recurrent gastric cancer successfully treated with TS-1', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 28, no. 4, pp. 539-542.
Onoda T, Okamura S, Takakura N, Shiozaki S, Ohno S, Higaki K et al. A case of recurrent gastric cancer successfully treated with TS-1. Gan to kagaku ryoho. Cancer & chemotherapy. 2001 Jan 1;28(4):539-542.
Onoda, T. ; Okamura, S. ; Takakura, N. ; Shiozaki, S. ; Ohno, S. ; Higaki, K. ; Ninomiya, M. ; Ikeda, Tetsuo ; Kobayashi, N. / A case of recurrent gastric cancer successfully treated with TS-1. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2001 ; Vol. 28, No. 4. pp. 539-542.
@article{77e4ea0cac7f415ca2bbad122a90f4a3,
title = "A case of recurrent gastric cancer successfully treated with TS-1",
abstract = "A patient with recurrent gastric cancer which infiltrated the pelvic muscle after the treatment of paraaortic lymph node and ovarian metastases was successfully managed by a novel oral anticancer drug, TS-1. TS-1 was administered at a dose of 80 mg/day. One course consisted of two repetitions of consecutive administration of TS-1 for 14 days and withdrawal of TS-1 for 14 days. Adverse reactions were mild and the patient did not request hospitalization after two courses had been completed. Subjective symptoms such as difficulty in walking improved after one week and a partial response was obtained after 2 weeks of treatment. At the end of 4 courses we could remove an indwelling pyelocatheter for the ureter stricture. As of 14 months after the beginning of administration of TS-1, the patient is being treated as an outpatient and has attained a better QOL than before.",
author = "T. Onoda and S. Okamura and N. Takakura and S. Shiozaki and S. Ohno and K. Higaki and M. Ninomiya and Tetsuo Ikeda and N. Kobayashi",
year = "2001",
month = "1",
day = "1",
language = "English",
volume = "28",
pages = "539--542",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - A case of recurrent gastric cancer successfully treated with TS-1

AU - Onoda, T.

AU - Okamura, S.

AU - Takakura, N.

AU - Shiozaki, S.

AU - Ohno, S.

AU - Higaki, K.

AU - Ninomiya, M.

AU - Ikeda, Tetsuo

AU - Kobayashi, N.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - A patient with recurrent gastric cancer which infiltrated the pelvic muscle after the treatment of paraaortic lymph node and ovarian metastases was successfully managed by a novel oral anticancer drug, TS-1. TS-1 was administered at a dose of 80 mg/day. One course consisted of two repetitions of consecutive administration of TS-1 for 14 days and withdrawal of TS-1 for 14 days. Adverse reactions were mild and the patient did not request hospitalization after two courses had been completed. Subjective symptoms such as difficulty in walking improved after one week and a partial response was obtained after 2 weeks of treatment. At the end of 4 courses we could remove an indwelling pyelocatheter for the ureter stricture. As of 14 months after the beginning of administration of TS-1, the patient is being treated as an outpatient and has attained a better QOL than before.

AB - A patient with recurrent gastric cancer which infiltrated the pelvic muscle after the treatment of paraaortic lymph node and ovarian metastases was successfully managed by a novel oral anticancer drug, TS-1. TS-1 was administered at a dose of 80 mg/day. One course consisted of two repetitions of consecutive administration of TS-1 for 14 days and withdrawal of TS-1 for 14 days. Adverse reactions were mild and the patient did not request hospitalization after two courses had been completed. Subjective symptoms such as difficulty in walking improved after one week and a partial response was obtained after 2 weeks of treatment. At the end of 4 courses we could remove an indwelling pyelocatheter for the ureter stricture. As of 14 months after the beginning of administration of TS-1, the patient is being treated as an outpatient and has attained a better QOL than before.

UR - http://www.scopus.com/inward/record.url?scp=0035316598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035316598&partnerID=8YFLogxK

M3 - Article

C2 - 11329792

AN - SCOPUS:0035316598

VL - 28

SP - 539

EP - 542

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -